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ABSTRACT Recent studies have underscored a role for the epicardium as a source of multi-
potent cells. Here, we investigate the myogenic potential of adult human epicardium-derived 
cells (EPDCs) and analyze their ability to undergo skeletal myogenesis when cultured with 
differentiating primary myoblasts. Results are compared to those obtained with mesenchy-
mal stromal cells (MSCs) and with endothelial cells, another mesodermal derivative. We dem-
onstrate that EPDCs spontaneously fuse with pre-existing myotubes with an efficiency that is 
significantly higher than that of other cells. Although at a low frequency, endothelial cells may 
also contribute to myotube formation. In all cases analyzed, after entering the myotube, 
nonmuscle nuclei are reprogrammed to express muscle-specific genes. The fusion compe-
tence of nonmyogenic cells in vitro parallels their ability to reconstitute dystrophin expression 
in mdx mice. We additionally show that vascular cell adhesion molecule 1 (VCAM1) expres-
sion levels of nonmuscle cells are modulated by soluble factors secreted by skeletal myo-
blasts and that VCAM1 function is required for fusion to occur. Finally, treatment with inter-
leukin (IL)-4 or IL-13, two cytokines released by differentiating myotubes, increases VCAM1 
expression and enhances the rate of fusion of EPDCs and MSCs, but not that of endothelial 
cells.
INTRODUCTION
Cell therapy is among the therapeutic approaches that can be pur-
sued to treat muscle degenerative disorders such as muscular dys-
trophy. Satellite cells and their myoblast progeny have the intrinsic 
capacity to repair multinucleated myofibers and constitute a natural 
reservoir of muscle precursors. Probably due to the continuous cy-
cles of degeneration and regeneration, the proliferation potential of 
satellite cells from Duchenne muscular dystrophy patients is re-
duced. Hence, alternative cells with myogenic capacity that can be 
easily harvested are being searched for as candidates for cell ther-
apy interventions.
Skeletal muscle cells inherently rely on cell fusion to gener-
ate functional tissue and may recruit non myogenic cells into 
cellular syncytia. Contribution by nonmuscle cells to regenerat-
ing myofibers may be determined either by autonomous trans-
differentiation toward the skeletal muscle phenotype or by 
fusion with pre-existing skeletal myotubes. Therefore, cells 
able to fuse with pre-existing muscle fibers may also provide a 
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and B). After the second culturing passage, EPDCs lose the epithe-
lial morphology and adopt a looser, mesenchymal-like appearance, 
suggestive of an EMT. Nonetheless, they maintain an epicardial 
phenotype, as indicated by the expression of the epicardial markers 
epicardin and Tbx18 (Figure 1, C and D).
To test whether EPDCs can be directed toward a skeletal muscle 
phenotype, we performed experiments in which EPDCs, previously 
infected with a lentiviral vector harboring a green fluorescent pro-
tein (GFP) expression cassette, were cocultured with equal amounts 
of unlabeled differentiating mouse primary myoblasts in an 80% 
confluent plate. Surprisingly, after 48 h in reduced-serum differentia-
tion medium (DM) many GFP+ contractile multinucleated cells were 
detected, indicating that EPDCs had been recruited to form skeletal 
myotubes (Figure 2A). The number of GFP+ myotubes corresponded 
approximately to 12% (12 ± 2%) of total myotubes, as calculated 
from three different experiments. When the GFP-labeled AT-MSCs 
were used, numerous GFP+ myotubes were also observed reaching 
a maximum of 5%. When GFP-labeled, endometrium-derived pri-
mary endothelial cells were used in the coculture, however, the 
number of GFP+ myotubes was markedly reduced compared to the 
other two cell types, and their number never exceeded 0.2% of total 
myotubes. To more precisely determine and compare the number 
of human nuclei incorporated into skeletal myotubes in the three 
cell types, coculture experiments with mouse myoblasts were per-
formed with unlabeled human cells and by plating at lower (30%) 
potent means for delivering molecules to skeletal muscle 
tissues.
The epicardium, which comprises the outermost layer of the 
heart and consists of mesothelial cells, is derived from a temporary 
structure of precursor cells with different developmental potentials 
termed the proepicardium. During embryogenesis, cells from the 
proepicardium emigrate toward the myocardial surface to form the 
epicardium. A fraction of epicardial cells, referred to as epicardium-
derived cells (EPDCs) then undergoes an epithelial-to-mesenchymal 
transition (EMT) and invades the heart, giving rise to endothelial 
cells, coronary smooth muscle cells, fibroblasts, as well as cells of 
the atrioventricular cushions. In addition, recent data show that epi-
cardial cells also make a substantial contribution to myocytes in the 
ventricular septum and the atrial and ventricular walls (Cai et al., 
2008; Zhou et al., 2008), although the evidence for such contribu-
tion has been recently questioned (Christoffels et al., 2009). EPDCs 
can be derived from adult human atrial appendages or epicardial 
adipose tissue (AT) biopsies and easily amplified in vitro. Cultured 
adult EPDCs are still able to undergo EMT and may differentiate into 
smooth muscle-like cells in vitro (Wada et al., 2003; van Tuyn et al., 
2007) and in vivo (Limana et al., 2007, 2009; Winter et al., 2007), 
suggesting that these cells may retain at least part of the differentia-
tion capacity present during embryonic development.
Previous data indicate that mesenchymal stromal cells (MSCs) 
derived from bone marrow (BM-MSCs) or AT (AT-MSCs) are able to 
generate hybrid myotubes when cocultured 
with differentiating myoblasts and may con-
tribute to myofiber formation by fusing with 
skeletal myotubes (Schulze et al., 2005; Di 
Rocco et al., 2006). EPDCs in the mesenchy-
mal status share with MSCs the ability to dif-
ferentiate into smooth muscle cells and os-
teoblasts, when grown with specific inductive 
media (van Tuyn et al., 2007). Whether EP-
DCs can also convert to the skeletal muscle 
phenotype has never been investigated.
The intrinsic plasticity of EPDCs prompted 
us to investigate whether human EPDCs, 
similarly to MSCs, could be recruited from 
myogenic cells to form skeletal myotubes 
and whether they could be effectively in-
duced to differentiate toward the myogenic 
lineage. Results were compared to those ob-
tained with AT-MSCs, which were used as a 
positive control, and to a distinct mesoderm-
derived lineage, endothelial cells. Our study, 
exploiting the formation of hybrid myotubes 
with human nonmuscle and murine myo-
genic cells, identifies EPDCs as a new cell 
type able to efficiently fuse with skeletal 
myotubes and provide some new hints on 
the process leading to the incorporation of 
nonmuscle cells into skeletal muscle.
RESULTS
EPDCs efficiently contribute to 
myotube formation when cocultured 
with myogenic cells
In vitro culture of epicardium dissected from 
human adult atrial appendages results in the 
outgrowth of cells with an epithelioid mor-
phology that expresses desmin (Figure 1, A 
FIGURE 1: Characterization of cultured EPDCs. Top: EPDCs at P0, just after the migration from 
the explant in bright field image (A) and stained with an antibody against desmin (red, B). 
Bottom: EPDCs at P1, stained with antibodies against the epicardial markers Epicardin (red,  
C) and Tbx18 (green, D). Nuclei are stained with Hoechst (blue). Magnification: A, 10×,  
Bar: 100 μm; B–D, 20×, Bars: 50 μm.
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density. Cells were then stained with an an-
tibody against Troponin T (TnT) to identify 
myotubes and with an antibody specific for 
human laminA/C, to identify human nuclei 
(Figure 2, D–F). In all three cases it was pos-
sible to detect skeletal myotubes containing 
from 1 to 3 human nuclei together with sev-
eral mouse nuclei. The fusion index, calcu-
lated as the ratio between the number of 
human nuclei inside myotubes and the total 
number of myotubes, was different, how-
ever, for the three cell types and was 
11.12% ± 4.23% for EPDCs, 5.06% ± 3.22% 
for AT-MSCs, and 0.20% ± 0.04% for en-
dothelial cells.
This result suggests that different cell 
types, although all of mesodermal deriva-
tion, display a different propensity to the re-
cruitment by skeletal myotubes. Because 
myotubes with only human nuclei could not 
be detected, it could be assumed that the 
recruitment of EPDCs, as well as of AT-MSCs 
and endothelial cells, into skeletal myotubes 
depends on fusion with mouse myotubes 
and not on cell-autonomous myogenic dif-
ferentiation. To confirm this point, coculture 
experiments were performed in Transwell 
dishes (Corning, Corning, NY), in which myo-
genic and nonmyogenic cells were sepa-
rated by a 0.4-μm filter, which does not allow 
cell mixing. In these conditions, no skeletal 
muscle differentiation markers were detect-
able in the tested human cells, indicating 
that the direct contact with mouse myoblasts 
is required to induce the expression of myo-
genic markers (unpublished data).
To test whether the fusion efficiency var-
ies with age or, in the case of MSCs, with the 
source tissue, we repeated the coculture ex-
periments with cells derived from patients 
of different ages and with stromal cells 
FIGURE 2: Human EPDCs, MSCs, and endothelial cells are incorporated into mouse 
skeletal myotubes and are reprogrammed to express human skeletal muscle specific 
genes. Adult EPDCs were cocultured with differentiating mouse primary myoblasts.  
Equal numbers of MSCs and endothelial cells were used for comparison. (A–C) Combined 
bright-field and green fluorescent protein (GFP) fluorescent (green) images of living cells. 
Human cells were labeled with a lentiviral vector expressing GFP. Several GFP-labeled 
multinucleated myotubes, indicating that human cells are participating in myotube 
formation, are visible with all three cell types. The number of green myotubes is much 
lower in the case of endothelial cells 
compared to EPDCs and MSCs. (D–F) 
Immunofluorescence of fixed cells labeled 
with antibodies that recognize both 
mouse and human Troponin T (hTNT, 
green) but only human LaminA/C (red). 
Several hybrid myotubes containing both 
human (red) and mouse (Hoechst blue) 
nuclei are visible. G–I: Fixed cells were 
stained with antibodies specific for hTnT 
(green) and human LaminA/C (red). 
Hoechst (blue) was used to visualize all 
nuclei. Independently from the cell origin, 
human nuclei inside hybrid myotubes are 
phenotypically reprogrammed to express 
skeletal muscle specific proteins. ENDO: 
endometrium-derived endothelial cells. 
Magnification: 20×, Bars: 50 μm. D′–F′, 
G′– I′: 2× enlarged boxes of D–F and G–I, 
respectively.
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served in sections from age-matched phosphate-buffered saline 
(PBS)-injected mice. Conversely, dystrophin was detected in up to 
10% (10.3 ± 2.3% in three different experiments) of the myofibers 
analyzed, corresponding to 1% of the entire area, on sections from 
EPDC-transplanted muscles, as revealed by immunofluorescence 
with an antibody against the C-terminal portion of mouse dystro-
phin (Figure 4). Dystrophin-positive fibers were organized in clus-
ters, suggesting clonal proliferation of donor cells. Analogous re-
sults, although with a reduced number of dystrophin-positive fibers 
(5.7 ± 1.5%, approximately 0.5% of the entire area), were obtained 
with AT-MSCs. Conversely, with endothelial cells the number of dys-
trophin-positive fibers was never higher than that of spontaneous 
revertants, corresponding to 0.1 ± 0.05% fibers (<0.01% of the area) 
in the 2-mo-old mdx mice used for our experiments.
These results show that administration of EPDCs effectively in-
duces the formation of dystrophin-expressing muscle fibers in mdx 
mice with a twofold efficiency compared to that of MSCs.
VCAM1 expression levels in human cells correlate with their 
fusion propensity and are modulated by soluble factors 
secreted by differentiating myoblasts
To understand the basis for the differential fusion ability of distinct 
cell types, we searched for fusion-related molecules that are not 
specific to the skeletal muscle phenotype and that could be differ-
entially expressed in the three cell types. Several adhesion mole-
cules are known to be involved in cell fusion processes. Among 
those, the α4 integrin receptor vascular cell adhesion molecule 1 
(VCAM1) has been reported to have a specific role in myotube for-
mation. VCAM1 (but not α4 integrin) is expressed in satellite cells 
and mononucleated myoblasts and it is required for their adhesion 
and/or fusion to myotubes (Rosen et al., 1992). By semiquantitative 
RT-PCR analysis we found that in both growth medium (GM) and 
DM culture conditions (Figures 5 and 6, respectively), VCAM1 ex-
pression levels effectively differ in the three cell types and correlate 
extracted from the cardiac biopsy instead of from subcutaneous ab-
dominal fat depots. In some cases we directly compared MSCs and 
EPDCs extracted from the same biopsy. We observed that, whereas 
age may actually have an adverse effect on the number of cells that 
overgrow from the biopsy and on their life span, it does not affect 
their ability to fuse with myotubes. Also, the fusion efficiency does 
not vary significantly if MSCs are extracted from subcutaneous AT or 
derived from cardiac biopsies. In all cases it never reached the level 
obtained with EPDCs. Finally, we tested different preparation of 
endometrium-derived endothelial cells as well as commercially 
available human umbilical venous cord endothelial cells (HUVECs). 
In all cases the percentage of fused cells was approximately 
0.2–0.3%. From our results we can therefore conclude that the high 
fusion efficiency is an intrinsic property of epicardial cells and that 
different cell types, although sharing a common mesodermal origin, 
may have different fusion propensity.
Human nuclei inside myotubes are reprogrammed to 
express human skeletal muscle–specific genes downstream 
of MyoD
To test whether human nuclei recruited from mouse myotubes were 
reprogrammed to express skeletal muscle–specific proteins, cocul-
ture plates were immunostained with an antibody against human 
TnT (hTnT) that recognizes the human but not the mouse protein. 
Results show that hTnT is synthesized by all myotubes containing 
human nuclei, independently from their cell origin. As it can be ob-
served in Figure 2, G–I, hTnT staining is always localized in the prox-
imity of human nuclei (identified by the reaction with the anti–human 
lamin A/C antibody) and fades around mouse nuclei. As expected, 
no staining was detected when EPDCs, endothelial cells, and 
AT-MSCs were cultured alone or in plates containing only mouse 
myotubes. These results show that, independently of cell origin, 
after entering the myotube nuclei are reprogrammed to express 
human muscle-specific genes.
To determine the extent of human nuclear reprogramming by 
mouse myotubes, coculture experiments with human nonmuscle 
cells and mouse primary myoblasts were analyzed by reverse tran-
scription–polymerase chain reaction (RT-PCR) with human specific 
primers for several muscle markers (Figure 3). Results were similar 
with all three cell types tested. Among the analyzed markers, the 
expression of the muscle-specific transcription factor MyoD and 
myogenin, as well as of late differentiation markers, such as the cho-
linergic nicotinic receptor CHRNA1 and the skeletal muscle myosin 
heavy chain MYH2, was detected in the presence but not in the 
absence of mouse myoblasts. A low level of MYH2, but not of other 
myogenic markers, could be consistently detected for AT-MSCs also 
in the absence of mouse skeletal muscle cells (Figure 3, lane 5). No 
human transcripts were detected, however, for early myogenic 
markers, such as Pax7 and Myf5, suggesting that reprogramming is 
limited to myogenic markers downstream from the master transcrip-
tion factor MyoD.
Transplantation of EPDCs and MSCs but not endothelial 
cells rescues dystrophin expression in mdx mice
To further assess the myogenic differentiation potential of EPDCs, 
we wanted to investigate whether EPDCs can be recruited to form 
skeletal myofibers in vivo. EPDCs cultured for not more than two 
passages were injected into the tibialis anterior (TA) muscle of phar-
macologically immunosuppressed mdx mice. As in the previous ex-
periment, AT-MSCs and endothelial cells at P2 were used for com-
parison. Ten days after injection, less than 0.1% dystrophin-positive 
fibers, corresponding to spontaneously revertant fibers, were ob-
FIGURE 3: RT-PCR analysis for skeletal muscle markers of human cells 
cocultured with mouse myoblasts. Human cells were cultured for 48 h 
in DM in the absence or presence (+) of differentiating mouse primary 
myoblasts. mRNA expression was evaluated by RT-PCR analysis. With 
the exception of β-actin (β-act) in lane 2, primers were selected so to 
be specific for human transcripts only. MYO: human skeletal muscle 
positive control; ENDO: endometrium-derived endothelial cells; 
Myog: Myogenin; CHRNA1: cholinergic nicotinic receptor A1; MYH2: 
adult skeletal myosin heavy chain.
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man receptor. In fact, the addition of mouse 
recombinant IL-4 in the culture medium 
does not elicit the same VCAM1 response 
obtained with the human molecule. As a 
consequence, VCAM1 induction in human 
cells by mouse MCM cannot be mediated 
by IL-4 secreted by mouse myotubes: IL-13, 
or other cross-species reactive soluble fac-
tors, must be responsible for the observed 
effect.
IL-4 and IL-13 positively modulate 
myotube recruitment of EPDCs and 
AT-MSCs but not endothelial cells
It has been reported that fusion of mouse 
BM-MSCs to differentiating skeletal mus-
cle cells is increased in the presence of ex-
ogenously added IL-4 (Schulze et al., 
2005). To test whether the same applies to human cells, we per-
formed coculture experiments in the presence of IL-4 or IL-13. 
The addition of either one of the two cytokines did not signifi-
cantly affect the fusion with myotubes of endothelial cells (unpub-
lished data). In contrast, treatment with human IL-4 or with the 
cross-species reactive mouse IL-13, determined an increment of 
the number of fusion events for both EPDCs and AT-MSCs 
(Figure 7A). In particular, IL-4 increased the percentage of fusion 
by approximately 35% and 15% in EPDCs and AT-MSCs, respec-
tively, whereas IL-13 raised the percentage by 20% in EPDCs and 
with their fusion propensity. In fact, EPDCs express relatively high 
VCAM1 levels, approximately twice as high as AT-MSC, whereas en-
dothelial cells express only basal levels, in particular when cultured 
in DM (Figure 6, compare lanes 1, 4, and 7).
Interestingly, in all three cell types the level of VCAM1 is signifi-
cantly increased by the presence of mouse myoblast-conditioned 
medium (MCM) as demonstrated by coculture experiments con-
ducted on Transwell dishes (Figure 5, lanes 2, 4, and 6). The level of 
VCAM1 induction is approximately twofold (100% increase) in AT-
MSCs and endothelium, whereas it is weaker (approximately 20% 
increase) in EPDCs, probably because EPDCs express an already 
high basal level of VCAM1 messenger RNA (mRNA). In parallel we 
analyzed the expression of ICAM1, a VCAM1-related adhesion 
mole cule at least so far not known to be involved in fusion pro-
cesses. Contrarily to VCAM1, the expression level of ICAM1 is simi-
lar in all cell types tested and is not modulated by MCM (Figure 5).
These results indicate that VCAM1 expression is induced by sol-
uble factors secreted by differentiating myoblasts. Data in the litera-
ture demonstrate that IL-4 is secreted by nascent myotubes and acts 
as a recruitment factor for myoblasts. The addition of IL-4, or of the 
common receptor ligand IL-13, to differentiating mouse myoblasts 
has a direct effect on myotube size, determining an increment on 
the number of nuclei per myotube (Horsley et al., 2003). VCAM1 
expression is induced by both IL-4 and IL-13 in endothelial cells 
(Bochner et al., 1995). Moreover, we have evidence that treatment 
with IL-4 or IL-13 positively modulates VCAM1 mRNA level in hu-
man myoblasts, suggesting that the modulatory effect of those cy-
tokines on cell fusion may be mediated at least in part by VCAM1 
(Gentile and Di Rocco, unpublished data). We therefore tested 
whether IL-4 and IL-13 similarly induce VCAM1 expression in EPDCs 
and AT-MSCs. To mimic the coculture conditions, cells were cultured 
in the presence of IL-4 or IL-13 for 48 h in DM. Treatment with either 
one of the human recombinant proteins effectively increases the 
mRNA level of VCAM1 in all cell types tested (Figure 6). The fold 
induction is again reduced (but statistically significant) in EPDCs, 
also in this case probably because these cells express already much 
higher levels of VCAM1 mRNA in the absence of treatment. Similar 
to what was observed in the presence of MCM, ICAM1 expression 
is not modulated by IL-4 or IL-13 treatment.
These results indicate that the VCAM1 induction observed with 
MCM is mimicked by IL-4 and IL-13, which are both known to 
be secreted by differentiating myoblasts (Horsley et al., 2003; 
Jacquemin et al., 2007). It must be noted, however, that IL-4 is 
species-specific, so that the mouse protein does not bind to the hu-
FIGURE 5: VCAM1 is expressed in nonmuscle human cells and is 
positively modulated in the presence of myoblast-conditioned 
medium. Human cells were cultured in GM on 0.4-μm transwell filters 
for 48 h in the absence or presence (+) of mouse differentiating 
myoblasts seeded at confluence in the lower chamber. mRNA 
expression was evaluated by semiquantitative RT-PCR analysis. PCR 
products were subjected to electrophoresis in agarose gel, visualized 
by ethidium bromide staining (A), and quantified by densitometric 
computer software after normalization for β-actin (B). A representative 
experiment is provided in (A). Values are the mean ± standard error of 
the mean (SEM) of three separate experiments. *p < 0.05; **p < 0.005.
FIGURE 4: Transplantation of EPDCs and MSCs but not endothelial cells rescues dystrophin 
expression in mdx mice. TA transverse sections from transplanted mdx mice. Staining for 
dystrophin (red) was performed 7 d after injection. Nuclei are visualized by Hoechst (blue). 
Several clusters of dystrophin-positive fibers can be detected in mice that received injections 
with EPDCs and MSCs, whereas the number of dystrophin-positive fibers detected with 
endothelial cells (ENDO) does not goes beyond the number of revertant fibers present in 
uninjected controls. Magnification: 40×, Bar: 25 μm.
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(Figure 7B). In addition, with both cell types, 
blocking of VCAM1 function almost totally 
quenched the stimulatory effect of IL-4 (Fig-
ure 7B). The recruitment of endothelial cells 
seemed to be negatively affected as well, 
however, due probably to the extremely low 
number of fusion events. Results obtained 
were never statistically significant (unpub-
lished data). All together these results show 
that, at least in the case of EPDCs and MSCs, 
VCAM1 is involved in the fusion of nonmus-
cle cells with skeletal myotubes. More im-
portantly, they suggest that the increment of 
VCAM1 expression possibly mediates the 
positive effects of IL-4 on cell recruitment 
inside multinucleated myotubes.
Knockdown of VCAM1 and IL-4Rα 
expression confirms their positive and 
connected role in the fusion process
To exclude possible unspecific effects of 
the anti-VCAM1 antibody, we performed 
coculture experiments with EPDCs and 
AT-MSCs in which VCAM1 expression was 
knocked down by the use of specific short 
hairpin RNA (shRNA). As an additional con-
trol, parallel experiments were also per-
formed with cells where the expression of 
IL-4 receptor α (IL-4Rα), which mediates 
both IL-4 and IL-13 signaling, had been 
suppressed. The inhibition of RNA tran-
scription by shRNA was evaluated by 
RT-PCR (Figure 8A). VCAM1 and IL-4Rα ex-
pression were reduced by approximately 
65% by their specific shRNAs in both cell 
types (Figure 8A). In addition, whereas, as 
expected, IL-4Rα expression was not af-
fected by VCAM1 suppression, VCAM1 expression was robustly 
reduced in IL-4Rα knockout cells, indicating that even basal levels 
of VCAM1 mRNA require IL-4Rα signaling (Figure 8A, lanes 3 and 
6). Such reduction was also nicely confirmed by immunostaining 
for VCAM1 on silenced cells (Supplemental Figure 1). Consistent 
with the results obtained with the neutralizing anti-VCAM1 anti-
body, suppression of VCAM1 expression in human nonmuscle cells 
inhibits their rate of fusion with mouse myotubes roughly by 50% 
and abrogates the inductive effect of IL-4 addition (Figure 8B). 
Moreover, similar results were obtained when IL-4Rα expression 
was suppressed. All together these results not only confirm 
the role of VCAM1 and IL-4R signaling in the fusion process, but 
also strengthen the new concept that VCAM1 is a mediator of 
IL-4/IL-13 fusion-promoting effect.
Differential expression of fusion-related genes
One possibility for the extremely low fusion competence of en-
dothelial cells could be that they fail to express some fusion-related 
genes when compared to fusion-competent cells such as EPDCs 
and MSCs. To verify such a hypothesis, we conducted a mini-screen-
ing by RT-PCR for the expression of various genes known to be in-
volved in the fusion process and at the same time tested whether 
they are modulated by IL-4. Those genes include the metallopro-
tease ADAM12, the mannose receptor (MRC1), Netrin3 (NTN3), the 
integrin chains α9 (ITGα9) and the isoform A and D of integrin β1 
30% in AT-MSCs (Figure 7A). Interestingly, treatment with mouse 
recombinant IL-4 also significantly enhanced the fusion rate to 
similar (in the case of EPDCs) or even higher (in the case of AT-
MSCs) levels when compared to the human protein. Moreover, if 
the two proteins (human and mouse IL-4) are added together, 
their effect is additive. Because the mouse protein may only act 
on mouse cells, its effect on human cell recruitment has to be in-
direct. These results suggest that additional mechanisms, proba-
bly acting also on recruiting myotubes and not only directly on 
recruited cells, may mediate the effects of IL-4 on myotube 
growth.
Blockade of VCAM1 function inhibits recruitment of EPDCs 
and AT-MSCs inside myotubes and abrogates the 
stimulatory effect of IL-4
To test whether VCAM1 is necessary for the fusion of nonmuscle 
cells to skeletal muscle, cocultures of human cells with murine pri-
mary myoblasts were carried out in the presence of a blocking anti-
VCAM1 antibody that specifically recognizes the human but not the 
mouse protein. As expected, and contrary to what happens with an 
antibody directed toward the mouse protein, the use of a human-
specific antibody did not change the fusion index as well as the av-
erage myonuclear number of mouse muscle cells. The number of 
human nuclei recruited by mouse myotubes, however, was consid-
erably decreased by approximately 30% for EPDCs and AT-MSCs 
FIGURE 6: IL-4 and IL-13 induce VCAM1 expression. Human cells were cultured for 48 h in DM 
in the absence or presence (+) of IL-4 or IL-13. mRNA expression was evaluated by 
semiquantitative RT-PCR analysis. PCR products were visualized by ethidium bromide staining on 
agarose gels (A) and quantified by densitometric computer software after normalization for 
β-actin (B). A representative experiment is provided in (A). Values are the mean ± SEM of three 
separate experiments. *p < 0.05; **p < 0.005.
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could be provided by muscle cells, as well 
as 2) fusion molecules already known to be 
expressed in endothelial cells. Interestingly, 
with the exception of VCAM1, all the tested 
molecules resulted to be expressed at com-
parable levels in EPDCs and AT-MSCs (Fig-
ure 9). The expression of ITGβ1D and ITGα7, 
however, was practically undetectable in en-
dothelial cells both in the presence and ab-
sence of IL-4. Moreover, apart from a mild 
inductive effect on MRC1 of approximately 
20%, confirmed by normalized densitome-
try data (unpublished data), none of the an-
alyzed genes seemed to be affected by 
treatment with IL-4. Thus, the inability to ex-
press some fusion-related genes may effec-
tively explain the reduced fusion propensity 
of endothelial cells.
Dissecting the pathway leading to 
VCAM1 induction by IL-4 and IL-13
In hematopoietic cells, IL-4 signals can use 
two different receptor types: the Type I 
receptor, which is composed of the IL-4Rα 
and the common γ-chain (γC) subunits, or the 
Type II receptor, which is composed of the 
IL-4Rα and IL-13Rα1 subunits. In nonhe-
matopoietic cells, including endothelial cells, 
fibroblasts, smooth muscle cells, and mesen-
chymal cells, the γC is not expressed and IL-4 
and IL-13 signal exclusively through the 
common Type II receptor. Both Type I and 
Type II receptor complexes signal through 
the Jak/STAT cascade (Jiang et al., 2000). A 
second mechanism of signal transduction 
activated by IL-4 and IL-13 leads to the insu-
lin receptor substrate family and the down-
stream phosphoinositide 3-kinase (PI3K). 
IL-4 is also known to initiate activation of 
MEK subfamilies, including ERK1/2, in bron-
chial smooth muscle and epithelial cells 
(Kelly-Welch et al., 2003). Finally, more re-
cent data identify P38MAPK as an additional 
mediator of IL-4R signaling (Canfield et al., 
2005; Jang et al., 2009).
To understand which of these pathways 
mediates VCAM1 induction by IL-4 and IL-
13 in different cell types, we cultured EP-
DCs, MSCs, and endothelial cells with IL-4 
or IL-13 in the presence of specific inhibitors 
and then evaluated VCAM1 mRNA levels 
by semiquantitative RT-PCR. Induction of 
VCAM1 by either IL-4 or IL-13 is blocked by 
inhibitors of either the PI3K or p38MAPK 
pathways (LY294002 and SB203580, respec-
tively; Figure 10). The effect is weak but consistent in EPDCs, where 
VCAM1 has higher basal levels, and more pronounced in MSCs and 
endothelial cells, as is evidenced by normalized densitometric data 
(Figure 10B). It has been suggested, but not conclusively demon-
strated, that in endothelial cells, stimulation of VCAM1 expression 
by IL-4/IL-13 may be mediated by the activation of Jak/2Stat6 
(Palmer-Crocker et al., 1996). We therefore tested the effect of a 
(ITGβ1A and ITGβ1D) (Schwander et al., 2003; Kang et al., 2004; 
Jansen and Pavlath, 2006, 2008; Quach et al., 2009). In addition, we 
included integrin α7 (ITGα7), which, although it has never been di-
rectly reported to be involved in fusion, represents the tissue-spe-
cific partner subunit of ITGβ1D (Mayer, 2003). We excluded from the 
screening molecules 1) those molecules that could act nonautono-
mously, such as soluble factors, because in a coculture system they 
FIGURE 7: Recruitment of EPDCs and MSCs inside myotubes is stimulated by IL-4 and IL-13 
while it is inhibited by VCAM1 blocking antibody. Human cells were cocultured with 
differentiating primary mouse myoblasts in presence of the indicated molecules for 2 d in DM. 
hIL-4: human recombinant IL-4; mIL-4: mouse recombinant IL-4; mhIL-4: mouse plus human IL-4; 
VCMab: specific anti–human VCAM1 antibody. The percentage of human nuclei inside myotubes 
was determined as the ratio between human lamin A/C-labeled nuclei inside TnT-labeled 
myotubes and the total number of human nuclei. Values are the mean ± SEM of three separate 
experiments. *p < 0.05; **p < 0.005.
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potent Jak2 inhibitor, W0894, on VCAM1 induction. Surprisingly, 
both basal and induced VCAM1 mRNA levels were unaffected by 
treatment with W0894 in all cell types tested (Figure 10), suggest-
ing that the activation of Jak2 is not required for IL-4R–mediated 
VCAM1 induction. Finally, VCAM1 induction was unchanged by 
treatment with the ERK1/2 pathway inhibitor PD98059 in all cell 
type tested (unpublished data).
DISCUSSION
Cells able to fuse with pre-existing muscle fibers, possibly ge-
netically engineered, may provide a potent means for delivering 
proteins to diseased skeletal muscle tissues. This study identifies 
the mesothelium-derived EPDCs as a new cell type able to effi-
ciently fuse with skeletal myotubes. Taking advantage of the for-
mation of hybrid myotubes by human nonmuscle and murine 
myogenic cells, we estimated that the percentage of epicardial 
nuclei inside myotubes after 48 h of coculture in DM reaches an 
average of 10% of total nuclei input. This percentage is particu-
larly high, considering that with MSCs 
obtained from the same or other sources 
it never goes beyond 5% in our culture 
conditions.
Several adult cell types have been re-
ported to be able to spontaneously fuse 
with myotubes. These include primary fibro-
blasts from different locations (Breton et al., 
1995; Salvatori et al., 1995), BM-MSCs (Shi 
et al., 2004; Lee et al., 2005; Schulze et al., 
2005), AT-MSCs (Di Rocco et al., 2006), peri-
cytes (Dellavalle et al., 2007; Kirillova et al., 
2007), and other BM-derived cells (Sacco 
et al., 2005). The fusion efficiency varies with 
cell types. Relatively high fusion efficiency, 
however, is observed with adherent cells 
such as fibroblast and stromal cells, whereas 
nonadherent hematopoietic cells and mono-
cytes are refractory to fusion (Shi et al., 2004) 
or fuse with an extremely low efficiency 
(Sacco et al., 2005).
In this regard, it is interesting to note 
that, as only recently emphasized, MSCs, fi-
broblasts, and pericytes share many pheno-
typical markers (Covas et al., 2008) and are 
probably considered variations of a unique 
phenotype (Bianco et al., 2008; da Silva 
Meirelles et al., 2008; Haniffa et al., 2009). 
In this context, the ability to assume a mes-
enchymal phenotype and differentiate to-
ward a smooth muscle lineage can in part 
explain the propensity of EPDCs to fuse with 
myotubes.
Former studies from Helen Blau’s labora-
tory have analyzed gene expression in het-
erokaryons of muscle and nonmuscle cells 
generated by addition of polyethylene gly-
col (PEG). These studies revealed significant 
similarities between heterokaryons repro-
gramming and muscle differentiation and 
showed that, although cells from nonmeso-
dermal lineages reprogram at lower efficien-
cies than do fibroblasts, in all cases nuclear 
reprogramming involves the activation of 
several skeletal muscle differentiation genes (Blau et al., 1985; 
Pomerantz et al., 2009). An extensive analysis of nuclear reprogram-
ming with spontaneously fused hybrid myotubes, including early 
and late skeletal markers, has never been reported, however. More-
over, whereas PEG-induced fusion is independent from the degree 
of differentiation, spontaneous fusion may occur only at a specific 
myoblast differentiation stage. Gene expression analysis of cocul-
tured cells revealed that EPDC (as well as endothelium and MSC) 
nuclei inside myotubes are reprogrammed to express human skel-
etal muscle specific genes and that such reprogramming involves a 
wide array of muscle markers downstream of MyoD. Early genes, 
such as the satellite cells marker Pax7 and the activated myoblast 
marker Myf5, were never detected. This was possibly because non-
muscle cells fuse with multinucleated myotubes, which no longer 
express early genes but are unable to fuse with mononucleated 
myoblasts (Sacco et al., 2005), as also suggested by the fact that 
hybrid myotubes always contains at least three mouse nuclei. To our 
knowledge, our studies for the first time also demonstrated that 
FIGURE 8: mRNA silencing of VCAM1 or IL-4Rα inhibits fusion of EPDCs and MSCs with 
myotubes. Human cells were infected with lentiviral vectors encoding for specific shRNA against 
VCAM1 or IL-4Rα. mRNA expression was evaluated by semiquantitative RT-PCR analysis and 
normalized for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (A). Cells were then 
cocultured with differentiating primary mouse myoblasts in the absence or presence of IL-4 for  
2 d in DM. The percentage of human nuclei inside myotubes was determined as the ratio 
between human lamin A/C-labeled nuclei inside TnT-labeled myotubes and the total number of 
human nuclei (B). Vcm: VCAM1; Il4R: IL4Rα. Values are the mean ± SEM of three separate 
experiments. Values of p between each test sample compared to its own control were all < 0.005.
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(although with reduced efficiency compared to other cells) endothe-
lial cells can fuse with myotubes and undergo nuclear reprogram-
ming toward the muscle phenotype. It seems therefore that, al-
though fusion efficiency may vary extensively, as soon as nuclei 
enter a myotube, transcription of muscle-specific genes is enabled, 
as indicated by the expression of human muscle proteins and in 
analogy to what was observed with PEG-induced heterokaryons.
The molecular cues that direct muscle cell fusion are not com-
pletely understood, although several molecules that facilitate fu-
sion have been defined recently (Jansen and Pavlath, 2008). The 
formation of multinucleated myotubes is a two-step process that 
begins with fusion between individual mononucleated cells (first 
step), and is then followed by myotube–myotube and myoblast–
myotube fusion (second step). Although probably several mole-
cules are involved and required for both steps, emerging data 
assign to secreted cytokines, such as IL-4, a specific role in the 
second step, that is the recruitment of additional nuclei to already 
multinucleated myotubes. As previously mentioned, our data in-
dicate that fusion of human nonmuscle cells occurs with multinu-
cleated myotubes and not with myoblasts. This fact would imply 
that molecules known to modulate the secondary fusion events 
could also affect the recruitment of nonmyogenic cells. It has been 
reported that fusion of mouse BM-MSCs to differentiating skeletal 
muscle cells is also regulated by IL-4 (Schulze et al., 2005). To test 
whether the same applies to different types of human cells as well, 
coculture experiments were performed in the presence of IL-4 or 
with the alternative IL-4 receptor (IL-4R) ligand, IL-13. Results 
show that, whereas the fusion efficiency of endothelial cells was 
not significantly affected by cytokine treatment, both IL-4 and IL-
13 determined an increment in the fusion/recruitment efficiency 
of both EPDCs and AT-MSCs, although to a reduced extent com-
pared to the increment of 200% previously reported for mouse 
BM-MSCs.
IL-4R target genes, which mediate the IL-4/IL-13 effect on muscle 
fusion, have not been identified. VCAM1 is an adhesion molecule 
that has been reported to be involved in myotube formation (Rosen 
et al., 1992). We observed that VCAM1 expression levels in different 
human cells correlate with their fusion propensity, and we showed 
that the inhibition of VCAM1 function hampers the fusion process 
between nonmuscle cells and skeletal myotubes. Additionally, we 
found that in human EPDCs, MSCs, and endothelial cells, VCAM1 
levels are modulated by soluble factors secreted by differentiating 
myoblasts and that this effect is mimicked by treatment with IL-4 or 
IL-13. These results suggest that VCAM1 is required for the fusion 
between myotubes and nonmuscle cells and, more importantly, that 
the fusion rate increase obtained upon IL-4 or IL-13 treatment is 
mediated at least in part by VCAM1 induction. The finding that a 
VCAM1 blocking antibody, as well as VCAM1 gene silencing, abro-
gate the stimulatory effects of IL-4 on myotube cell recruitment also 
corroborates such a hypothesis.
The use of the non-cross-reactive murine and human forms of 
IL-4 in our two-species hybrid system revealed that IL-4 exerts a 
dual effect on the recruitment of nuclei inside the myotube: a di-
rect one on the target cell, in part possibly mediated by VCAM1 
induction, and an indirect one the mechanism of which remains 
unknown. As reported in the literature and as also observed in 
our cultures with murine IL-4, the presence of IL-4 during myo-
blasts differentiation shifts the balance between small and big 
myotubes, determining an increase in the average number of nu-
clei per myotubes. It is therefore possible that bigger myotubes 
have a higher recruitment ability, that is, are more prone to fusion 
than are small ones.
In endothelial cells, VCAM1 mediates the adhesion of a variety 
of cells, including lymphocytes and monocytes. Although en-
dothelial cells may strongly up-regulate VCAM1 expression in the 
presence of skeletal myoblasts, they never acquire a fusion com-
petence compared to the one of EPDCs or AT-MSCs. In fact, 
treatment with cytokines up-regulating VCAM1 increases the 
number of recruited nuclei in EPDCs and AT-MSCs but does not 
significantly alter the number of fusing endothelial cells. There-
fore, even if VCAM1 may be required, it is obviously not sufficient 
for the fusion process. One possibility is that endothelial cells lack 
part of the fusion machinery that is present in more fusion-com-
petent cells, such as EPDCs and MSCs, and that the rare fusion 
events that are observed may occur through a different mecha-
nism. Our finding that endothelial cells fail to express the fusion-
related gene ITGβ1D and its muscle-specific partner ITGα7, which 
instead are expressed in EPDCs and MSCs, would support such a 
hypothesis.
Finally, no conclusive data exist in the literature regarding the 
signaling pathways involved in VCAM1 induction by IL-4/IL-13. It 
has been recently reported that hypoxia-induced VCAM1 in mouse 
lung is significantly reduced in IL-4 knockout lungs but not in STAT6 
knockout lungs, suggesting that VCAM1 induction in the lungs oc-
curs via IL-4 but does not require a STAT6 pathway. This notion 
would be consistent with the fact that the VCAM1 promoter does 
not contain any STAT6-binding sites (Yamaji-Kegan et al., 2009). We 
show that VCAM1 induction in three nonhematopoietic cell types is 
negatively affected by PI3K and p38MAPK inhibitors but not by 
ERK1/2 or Jak2 inhibitors. Although our data do not exclude that 
Stat6 could be involved in any way, it is plausible to assume that 
VCAM1 induction by IL-4R Type II is mediated primarily by the PI3K 
and p38MAPK pathways.
FIGURE 9: Expression of fusion-related genes in human nonmuscle 
cells. Human cells were cultured for 48 h in DM in the absence or 
presence (+) of IL-4. mRNA expression was evaluated by 
semiquantitative RT-PCR analysis. Human myoblasts (MYO) were used 
as positive control. ADAM12: disintegrin and metalloproteinase 
domain-containing protein 12; MRC1: mannose receptor isoform 1; 
NTN3: Netrin3.
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the biopsy from floating. DMEM and M199 
at a 1:1 (vol/vol) ratio supplemented with 
10% fetal bovine serum (FBS), 1% penicillin–
streptomycin (Gibco, Carlsbad, CA), and 
basic fibroblast growth factor (bFGF) at 
2 ng/ml was used as culture medium. After 
outgrowth of the cells, the epicardium was 
removed and the cells were cultured for one 
or two passages.
MSC isolation
Subcutaneous AT biopsies of abdominal 
origin or atrial appendages after epicar-
dium removal were digested with Collage-
nase A (Roche, Basel, Switzerland) at 
2 mg/ml for 40 min at 37°C. A single-cell 
suspension was obtained after filtering 
through a 40-μm cell strainer and centri-
fuged. Cells were plated on an uncoated 
culture tissue dish in DMEM, 20% FBS, and 
1% penicillin–streptomycin, 2 mM glu-
tamine and were washed after 8 h to re-
move nonadherent cells. Both AT-MSCs 
and atrial MSCs were amplified in culture 
for three passages. Cell populations were 
checked for the presence of typical stromal 
antigens by fluorescence-activated cell 
sorting (FACS) analysis as previously de-
scribed (Zuk et al., 2002).
Endometrial endothelial cells isolation
Endometrium samples obtained upon 
scraping were incubated in M199 medium 
containing 0.2% Collagenase Type II at 
37°C for 2 h. After centrifugation, the 
pellet was resuspended in culture me-
dium and transferred to fibronectin-
coated culture dishes. Two to four hours 
later, the nonadherent cells were re-
moved, and the adherent cells were 
cultured in a medium consisting of 
M199 additioned with 20% FBS, 5 U/ml 
heparin, 5 mg/ml endothelial cells growth 
supplement (BD, Franklin Lakes, NJ), and 
5 ng/ml VEGF. The primary heteroge-
neous cell population was grown until 
near confluence, then endothelial cells 
were selected by anti–human CD31-
coated microbeads (miniMACS, Miltenyi, 
Auburn, CA), according to the manufac-
turer’s instructions. Two rounds of CD31 selection were per-
formed to obtain a purity of approximately 99% CD31+ cells, as 
assessed by flow cytometry.
Cocultures with murine primary myoblasts
Primary myoblasts were obtained as described (Di Rocco et al., 
2006). Briefly, hind-limb muscles of 4-wk-old CD1 mice were minced 
by scissors, then digested with collagenase/dispase (Roche) at 
2 mg/ml at 37°C. Cells were preplated on uncoated culture tissue 
dishes overnight and then transferred to fibronectin-coated dishes 
in GM consisting of DMEM, 20% FBS, 1% penicillin–streptomycin, 
2 mM glutamine, and bFGF at 5 ng/ml. When myoblasts were 
MATERIALS AND METHODS
All experimental procedures complied with the Italian National Insti-
tutes of Health and were approved by the Institutional Animal Care 
and Use Committee. All experiments with human tissue were car-
ried out according to the Local Ethics Committee and upon obtain-
ing a written informed consent signature.
Epicardial cell isolation
EPDCs were obtained from atrial appendages of patients from 50 to 
80 yr old undergoing cardiac surgery. The epicardial layer was sepa-
rated mechanically from the biopsy, immediately placed in a fi-
bronectin-coated dish, and covered by a glass coverslip to prevent 
FIGURE 10: VCAM1 induction by IL-4/IL-13 requires the PI3K and P38MAPK pathways. EPDCs, 
MSCs, and endothelial cells were cultured with IL-4 or IL-13 in the presence of specific pathway 
inhibitors. VCAM1 mRNA expression levels were evaluated by semiquantitative RT-PCR. LY: 
LY294002 for PI3K; SB: SB202190 for P38 MAPK; W0: W0894 for Jak2. Values are the mean ± 
SEM of three separate experiments. P values between each test sample compared to its own 
control were all < 0.005.
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approximately 50% confluent, 105/cm2 human cells (EPDCs, MSCs, 
or endothelial cells) were added and allowed to adhere overnight; 
then the culture was switched to DM consisting of DMEM supple-
mented with 2% horse serum, to induce myotube formation.
Media supplements
Recombinant human IL-4 (Sigma, St. Louis, MO) or mouse IL-4 
(PreproTech, Rocky Hill, NJ) was added at 10 and 50 ng/ml, re-
spectively. Recombinant mouse IL-13 (PreproTech) was used at 
50 ng/ml. The blocking anti–human VCAM1 monoclonal anti-
body (clone CD106; R&D Systems, Minneapolis, MN) was used at 
3 μg/ml. Three different concentrations were tested for each sig-
naling pathway inhibitor (all from Sigma) and then used as 
follows: LY294002, 20 μm; SB202190, 30 μm; W0894, 2 μm; 
PD98059, 50 μm.
Lentivirus-mediated gene transfer
The third-generation lentiviral SIN (self-inactivating) vector pC-
CLsin.cPPT.hPGK.E-GFP.Wpre plasmid was a gift from Elisa Vigna 
(Follenzi et al., 2000). For viral transduction, cells were plated at 
60% confluence in their expansion medium and were transduced 
the next day with approximately 10 transforming units per cell of 
lentiviral vector stocks in the presence of 6 μg/ml Polybrene® 
(Abbott Laboratories Corp., Abbott Park, IL). After incubation at 
37°C from 1 h to overnight cells were trypsinized and subcultured 
at a 1:3 ratio and cultured for 2 more days before being used in 
subsequent experiments. Transduction efficiency was determined 
by FACS analysis and was estimated to be >90% in all cell types 
used.
Immunofluorescence
Antibodies were diluted (vol/vol) as follows: TBX18 (Santa Cruz Bio-
technology, Santa Cruz, CA), 1:100; Epicardin (Abcam, Cambridge, 
MA), 1:200; Desmin (Chemicon, Billerica, MA), 1:100; human Tro-
ponin-T (Abcam), 1:400; Troponin-T (Santa Cruz), 1:500; human Lamin 
A/C (Santa Cruz), 1:100; VCAM1 (R&D), 1:100. Secondary antibodies 
were 488/594 Alexa fluor-labeled anti–mouse/–rabbit or –goat im-
munoglobulin G (Molecular Probes, Carlsbad, CA).
RT-PCR
Total RNA was extracted using an RNeasy Mini kit (Qiagen, Valencia, 
CA) according to the manufacturer’s instructions. RNA was reverse 
transcribed with M-MLV reverse transcriptase (Promega, Madison, 
WI), using random hexamers. PCRs of cocultures were performed 
using primers specific for human sequences, not recognizing murine 
transcripts. Control RT reactions and the presence of introns span-
ning the amplified sequences excluded the possibility of any DNA 
contamination.
Surgical procedures for in vivo experiments
All mice were anesthetized with 2.5% Avertin (2,2,2-tribromoetha-
nol; Sigma-Aldrich, St. Louis, MO). A total of 1 × 105 cells, resus-
pended in 25 μl of PBS, were delivered into the tibialis anterior (TA) 
of 2-mo-old C57BL/10SnJ mdx mice (The Jackson Laboratory, Bar 
Harbor, ME). Age-matched mdx control animals received injections 
of PBS only. All injected animals received a daily injection of FK506 
at 2 mg/kg as immunosuppressant from the day before transplanta-
tion to killing 1 wk after injection.
Immunohistochemistry
TA muscles were removed and fixed in 10% formalin for 48 h and 
then were embedded in paraffin and sectioned at 5 μm. Sections 
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